• Adicet Bio posted a net loss of USD 20.2 million, or USD 1.88 per share, for first-quarter 2026, narrowing from a loss of USD 28.2 million, or USD 4.96 per share, a year earlier.
• R&D expense fell 23.33% to USD 17.5 million, while G&A expense dropped 42.25% to USD 4.1 million.
• Cash, cash equivalents and short-term investments declined to USD 137.6 million as of March 31 from USD 158.5 million at year-end, with funding expected to last into second-half 2027.
• Mid-2026 Phase 1 clinical update expected for prulacabtagene leucel in lupus nephritis and systemic lupus erythematosus with at least 20 patients and at least six months of follow-up; FDA interaction on potential pivotal-trial design expected in 2Q 2026.
• Regulatory filing for ADI-212 in metastatic castration-resistant prostate cancer targeted for 3Q 2026, with Phase 1 enrollment expected to start in 4Q 2026 pending clearance.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Adicet Bio Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605131601BIZWIRE_USPR_____20260513_BW189157) on May 13, 2026, and is solely responsible for the information contained therein.